Insulet PODD appears well-poised on solid prospects in the diabetes market. The company continues to gain from strong Omnipod 5 and Omnipod DASH uptake globally. The stock carries a Zacks Rank #1 ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...

Get key Q3 2025 earnings insights for Insulet (PODD): record revenue, robust growth in Type 1/Type 2 markets, upgraded guidance, and innovation updates.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Beyond Dash, Insulet has launched its hybrid closed-loop Omnipod 5 pump—a very compelling pump option, from our view. The pace of Insulet's innovation has quickened and has allowed the firm to come on ...

Insulet has begun a voluntary recall of the remote-control devices used with its Omnipod Dash insulin pumps after discovering that the devices’ batteries may be at risk of swelling, leaking or ...

Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.

Insulet Corporation PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. The stock carries a Zacks Rank #2 (Buy).

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod® 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 ...

Moderna’s bivalent COVID-19 booster increases antibodies by 15 times against Omicron subvariants; an Amazon virtual health clinic does not include health insurance and will vary in price depending on ...